



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/17	A1	(11) International Publication Number: WO 97/26004 (43) International Publication Date: 24 July 1997 (24.07.97)						
<p>(21) International Application Number: PCT/US97/00864</p> <p>(22) International Filing Date: 17 January 1997 (17.01.97)</p> <p>(30) Priority Data:</p> <table border="0"><tr><td>60/010,229</td><td>19 January 1996 (19.01.96)</td><td>US</td></tr><tr><td>9602408.8</td><td>7 February 1996 (07.02.96)</td><td>GB</td></tr></table> <p>(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY (US/US); Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BEALS, John, M. [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278-1853 (US). DODD, Steven, W. [US/US]; 4472 Andscott Drive, Indianapolis, IN 46254 (US). PEKAR, Allen, H. [US/US]; 5354 North Park Avenue, Indianapolis, IN 46220 (US).</p> <p>(74) Agents: CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p>		60/010,229	19 January 1996 (19.01.96)	US	9602408.8	7 February 1996 (07.02.96)	GB	<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report. Before the expiration of the time limits for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
60/010,229	19 January 1996 (19.01.96)	US						
9602408.8	7 February 1996 (07.02.96)	GB						
<p>(54) Title: OBESITY PROTEIN FORMULATIONS</p> <p>(57) Abstract</p> <p>The present invention discloses a soluble parenteral formulation, comprising obesity protein and a preservative selected from the group consisting of alkylparaben, chlorobutanol, or a mixture thereof.</p> <p style="text-align: center;">BEST AVAILABLE COPY</p>								